Light therapy is emerging as a promising, non-pharmacological treatment for Alzheimer’s disease, offering significant improvements in sleep and psycho-behavioral symptoms such as depression and ...
Wake Forest University School of Medicine researchers found that just 3½ years of intensive blood pressure control can ...
A new study from researchers at Wake Forest University School of Medicine shows that only 3.5 years of intensive blood ...
In a small cohort of adults in South Korea, the presence of cerebral small vessel disease was associated with color reading ...
CBT-E is a promising treatment for adolescents with eating disorders who did not fully recover from FBT or could not engage ...
The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer ...
Tisento Therapeutics has dosed the first subject in its Phase IIb PRIZM study, examining the effects of the oral ...
GlobalData on MSN5d
Eisai and Biogen’s Leqembi sBLA set for Alzheimer’s maintenance dosingThe US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...
A study by the (UPV/EHU) demonstrates that the drug WIN55,212-2 protects the brain and reverses early cognitive damage caused ...
A U.S. robotics company has developed Jennie, a robotic pet powered by artificial intelligence that's designed to comfort ...
The use of short-term hormone therapy for menopause is not associated with long-term cognitive impact after 10 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback